Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Urology

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2015.07.007PMID 26188394
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration‑Resistant Prostate Cancer

  2016influential reference
• Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer

  2015cited by this paper
• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

  2015cited by this paper
• Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

  2015cited by this paper
• Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

  2015cited by this paper
• Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014influential reference
• Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

  2014cited by this paper
• Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Clinical activity of enzalutamide in Docetaxel‐naïve and Docetaxel‐pretreated patients with metastatic castration‐resistant prostate cancer

  2014cited by this paper
• Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

  2014cited by this paper
• The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.

  2014cited by this paper
• Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics.

  2013cited by this paper
• Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

  2013cited by this paper
• Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells

  2009cited by this paper
• Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

  2009cited by this paper
• Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

  2009cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

  2008cited by this paper
• Cáncer

  1939cited by this paper

• Clinical impact of real‐time androgen receptor alteration monitoring on metastatic castration‐resistant prostate cancer treatment in real‐world settings

  2025cites this paper
• 20 years of taxane therapy in prostate cancer - the past, present and future.

  2025cites this paper
• Liquid biopsy – a narrative review with an update on current US governmental clinical trials targeting immunotherapy

  2025cites this paper
• Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer

  2025cites this paper
• Systems-level liquid biopsy in advanced prostate cancer.

  2025cites this paper
• Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis

  2025cites this paper
• The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate Cancer

  2025cites this paper
• Molekulare Tumorboards in der Uroonkologie – Prostatakarzinom

  2024cites this paper
• Clinical Implementation of a Noninvasive, Multi-Analyte Droplet Digital PCR Test to Screen for Androgen Receptor Alterations

  2024cites this paper
• The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide

  2024cites this paper
• How to Integrate Prostate Cancer Biomarkers in Urology Clinical Practice: An Update

  2024cites this paper
• Liquid biopsy to personalize treatment for metastatic prostate cancer.

  2024cites this paper
• Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer

  2024cites this paper
• Aptamers for the Delivery of Plant-Based Compounds: A Review

  2024cites this paper
• mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer

  2023cites this paper
• Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases

  2023cites this paper
• Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells

  2023cites this paper
• Cellular senescence: A potential mode of circular RNAs regulating prostate cancer

  2023cites this paper
• Liquid biopsy as a new tool for diagnosis, monitoring, and personalized medicine in urogenital cancers

  2022cites this paper
• Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel

  2022cites this paper
• Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells

  2022cites this paper
• Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer

  2022cites this paper
• Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer

  2022cites this paper
• A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways

  2022cites this paper
• Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis

  2022cites this paper
• Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

  2022cites this paper
• Factors influencing survival in metastatic castration-resistant prostate cancer therapy

  2022cites this paper
• Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer

  2022cites this paper
• Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer

  2022cites this paper
• Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

  2022cites this paper
• Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

  2021cites this paper
• Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer

  2021cites this paper
• Circular RNAs in prostate cancer: Biogenesis,biological functions, and clinical significance

  2021cites this paper
• Cross-resistance and drug sequence in prostate cancer.

  2021cites this paper
• New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer

  2021cites this paper
• Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.

  2021cites this paper
• Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management

  2021cites this paper
• Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment

  2021influential citation
• Repurposing of Camptothecin: An Esterase-Activatable Prodrug Delivered by a Self-Emulsifying Formulation that Improves Efficacy in Colorectal Cancer.

  2021cites this paper
• Tumor Cells in Prostate Cancer Diagnosis and Treatment

  2021influential citation
• Liquid biopsy in prostate cancer: current status and future challenges of clinical application

  2021cites this paper
• The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer

  2021cites this paper
• Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis

  2021cites this paper
• The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis

  2021influential citation
• Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer

  2021cites this paper
• Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.

  2021cites this paper
• AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption

  2021cites this paper
• Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

  2021cites this paper
• Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.

  2021cites this paper
• Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers

  2020cites this paper
• Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

  2020cites this paper
• Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients

  2020cites this paper
• Exploration of Circulating Tumour Cell (CTC) Biology: A Paradigm Shift in Liquid Biopsy

  2020cites this paper
• A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA–Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer

  2020cites this paper
• The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis

  2020cites this paper
• Biomarkers of response to advanced prostate cancer therapy

  2020cites this paper
• The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis

  2020cites this paper
• Liquid biopsy and prostate cancer. Current evidence applied to clinical practice

  2020cites this paper
• Fundamentals of liquid biopsies in metastatic prostate cancer: from characterization to stratification.

  2020cites this paper
• Radionuklidtherapie mit PSMA-Liganden bei fortgeschrittenem Prostatakarzinom

  2020cites this paper
• A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer

  2020cites this paper
• Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer.

  2020cites this paper
• Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients

  2020cites this paper
• AR-V7 Positivity Varies with Circulating Tumor Cell (CTC) Enrichment and Novel CTC Enrichment Is Able to Reduce AR-V7 False Positivity

  2020cites this paper
• Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer

  2020cites this paper
• The association between androgen receptor splice variant 7 status and prognosis of metastatic castration‐resistant prostate cancer: A systematic review and meta‑analysis

  2020cites this paper
• Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer

  2020cites this paper
• Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

  2020cites this paper
• Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.

  2020cites this paper
• Novel Nanococktail of a Dual PI3K/mTOR Inhibitor and Cabazitaxel for Castration‐Resistant Prostate Cancer

  2020cites this paper
• Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer

  2020cites this paper
• Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer

  2020cites this paper
• Clinical concepts for cabazitaxel in the management of metastatic castration‐resistant prostate cancer

  2019cites this paper
• Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide

  2019cites this paper
• Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes

  2019cites this paper
• Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti‐androgens

  2019cites this paper
• Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities.

  2019cites this paper
• Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

  2019cites this paper
• GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression

  2019cites this paper
• Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer

  2019influential citation
• Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients

  2019cites this paper
• Novel molecular targets in advanced prostate cancer

  2019cites this paper
• Current status of liquid biopsies for the detection and management of prostate cancer

  2019cites this paper
• Conventional and Novel Diagnostic Biomarkers and Approaches for Detection of Nasopharyngeal Carcinoma

  2019cites this paper
• The Significance of Circulating Tumour Cells in the Clinic

  2019cites this paper
• Liquid biopsy and minimal residual disease — latest advances and implications for cure

  2019cites this paper
• Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility.

  2019cites this paper
• Multiparametric liquid biopsy analysis in metastatic prostate cancer.

  2019cites this paper
• Considerations for AR-V7 testing in clinical routine practice.

  2019cites this paper
• Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope

  2019cites this paper
• Role of androgen receptor splice variants, their clinical relevance and treatment options

  2019cites this paper
• Liquid biopsy and prostate cancer. Current evidence applied to clinical practice.

  2019cites this paper
• Profiling Circulating Tumour Cells for Clinical Applications Profiling Circulating Tumour Cells for Clinical Applications

  2019cites this paper
• Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.

  2019cites this paper
• Liquid biopsies

  2019cites this paper
• Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.

  2019cites this paper
• CMAR_A_170380 5271..5291

  2019cites this paper
• Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel

  2019cites this paper
• AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel

  2019cites this paper
• Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications

  2019cites this paper